MEDI
NEO
saleprice
KONEF
OTC
Ketamine 1 Icon

Ketamine One Announces Intention to Submit Draft Registration Statement for Proposed U.S. Initial Public Offering

November 9, 2021

Director Steven Inglefield Has Also Been Appointed Chief Operating Officer of the Company  

Vancouver, British Columbia, November 9, 2021 / Globe Newswire / – KetamineOne Capital  Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt:  MY0), a company focused on consolidating medical clinics and becoming a North American  leader in mental health treatments, is pleased to announce that it intends to confidentially submit  a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission (the  "SEC") relating to a potential initial public offering (“IPO”) of its common shares in the United  States. The IPO is expected to be for up to USD 20 Million of Ketamine One’s common shares  and is currently expected by Company management to occur in the first half of 2022. The number  of common shares to be offered, the use of proceeds, and the price range for the proposed IPO  have not yet been determined.  

Steven Inglefield as COO  

Ketamine One is also pleased to announce that Steven Inglefield has been appointed as Chief  Operating Officer (“COO”) of the Company. Mr. Inglefield is the Founder of Integrated Rehab  and Performance Ltd., which was acquired by Ketamine One in June of 2021 and has since been  rebranded as IRP Health by the Company. Steven has over 16 years of experience in the health  and wellness sector in both private and public health. A serial entrepreneur and a Physiotherapist  by training, he has successfully started, managed and exited multiple health companies including  multidisciplinary health clinics, corporate wellness services, and personal training studios.  

Management Commentary  

“I would like to congratulate Steven on being promoted to COO of Ketamine One and thank him for his contributions to the Company to date. His entrepreneurial drive, leadership qualities and vision for the business have been a tremendous asset since Ketamine One acquired IRP earlier this year,” said Adam Deffett, Interim CEO of Ketamine One. “Now as COO and as a member of the 

Board of Directors, Steven is positioned to maximize his contributions to Ketamine One as we continue to grow our clinic network across Canada and the United States, to drive new business to KGK Science as our contract research organization, and to layer innovative technological solutions across both of those strategic pillars,” added Mr. Deffett. 

This news release does not constitute an offer to sell or the solicitation of an offer to buy any  securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in  accordance with the registration requirements of the Securities Act of 1933, as amended  ("Securities Act"). This announcement is being issued in accordance with Rule 135 under the  Securities Act.  

ABOUT KETAMINE ONE 

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on  consolidating medical clinics and becoming a North American leader in mental health treatments.  It is working to provide the critical infrastructure needed to develop and deliver breakthrough  mental health treatments. Currently, Ketamine One has a network of clinics across North America,  with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the  Company’s wholly-owned contract research division, which places it at the forefront of premium  clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals,  cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine  One is dedicated to helping solve the growing need for safe and accessible mental health therapy.  

On behalf of:  

KETAMINE ONE 

"Adam Deffett"  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-PHONE-K1 (1-844-746-6351)  

Email: IR@ketamine.one  

Web: www.ketamine.one 

Twitter: @KetamineOne  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known 

and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward 

looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.